IOVA IOVANCE BIOTHERAPEUTICS, INC.

Nasdaq iovance.com


$ 2.19 $ -0.06 (-2.68 %)    

Friday, 17-Oct-2025 18:55:05 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 2.18
$ 2.19
$ 2.16 x 75
$ 2.20 x 5,000
$ 2.13 - $ 2.24
$ 1.64 - $ 12.51
9,271,963
na
788.84M
$ 1.30
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 02-27-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 02-28-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-10-2023 03-31-2023 10-Q
11 02-28-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 02-24-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 02-25-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-05-2020 03-31-2020 10-Q
23 02-25-2020 12-31-2019 10-K
24 11-04-2019 09-30-2019 10-Q
25 08-01-2019 06-30-2019 10-Q
26 05-07-2019 03-31-2019 10-Q
27 02-28-2019 12-31-2018 10-K
28 11-06-2018 09-30-2018 10-Q
29 08-07-2018 06-30-2018 10-Q
30 05-10-2018 03-31-2018 10-Q
31 03-12-2018 12-31-2017 10-K
32 11-02-2017 09-30-2017 10-Q
33 08-03-2017 06-30-2017 10-Q
34 05-03-2017 03-31-2017 10-Q
35 03-09-2017 12-31-2016 10-K
36 11-04-2016 09-30-2016 10-Q
37 08-09-2016 06-30-2016 10-Q
38 05-09-2016 03-31-2016 10-Q
39 03-11-2016 12-31-2015 10-K
40 11-06-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 iovance-biotherapeutics--enters-amended-sale-agreement-with-jefferies-may-sell-up-to-350m-of-common-stock

-SEC Filing

 hc-wainwright--co-reiterates-buy-on-iovance-biotherapeutics-maintains-20-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and maintains $...

 iovance-biotherapeutics-receives-health-canada-nocc-for-amtagvi

First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD...

 wells-fargo-maintains-overweight-on-iovance-biotherapeutics-lowers-price-target-to-14

Wells Fargo analyst Yanan Zhu maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and lowers the price target ...

 chardan-capital-maintains-buy-on-iovance-biotherapeutics-lowers-price-target-to-20

Chardan Capital analyst Geulah Livshits maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and lowers the price targ...

 iovance-biotherapeutics-declines-29-in-premarket-trading-heres-whats-happening

Iovance stock fell over 29% pre-market after Q2 results, despite reporting a strong revenue jump led by Amtagvi sales.

 iovance-biotherapeutics-affirms-fy2025-sales-guidance-of-250000m-300000m-vs-300184m-est

Iovance Biotherapeutics (NASDAQ:IOVA) affirms FY2025 sales outlook from $250.000 million-$300.000 million to $250.000 million-$...

 iovance-biotherapeutics-q2-eps-033-misses-029-estimate-sales-59952m-miss-69792m-estimate

Iovance Biotherapeutics (NASDAQ:IOVA) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimat...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION